Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression.

Saved in:
Bibliographic Details
Title: Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression.
Authors: Rittig SM; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin, Berlin, Germany.; Berlin Institute of Health at Charité - Universitaetsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité (Junior) (Digital) Clinician Scientist Program, Berlin, Germany., Lutz MS; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany., Clar KL; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany., Zhou Y; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany., Kropp KN; Department of Hematology, Medical Oncology and Pneumology, University Medical Center of Mainz, Mainz, Germany., Koch A; Department of Obstetrics and Gynecology, University Hospital Tuebingen, Tuebingen, Germany., Hartkopf AD; Department of Obstetrics and Gynecology, University Hospital Tuebingen, Tuebingen, Germany.; Department of Gynecology and Obstetrics, University Hospital of Ulm, Ulm, Germany., Hinterleitner M; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.; Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany., Zender L; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.; Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany.; German Cancer Research Consortium (DKTK), Partner Site Tuebingen, German Cancer Research Center (DKFZ), Heidelberg, Germany., Salih HR; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany., Maurer S; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.; Precision Immunology Institute, Department of Oncological Sciences, and The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Hinterleitner C; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' , University of Tuebingen, Tuebingen, Germany.; Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany.; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Source: Frontiers in oncology [Front Oncol] 2022 Jul 08; Vol. 12, pp. 917834. Date of Electronic Publication: 2022 Jul 08 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2234-943X
DOI:10.3389/fonc.2022.917834